From: Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
SIRPα-Fc fusion | Company | IgG | Indications | Monotherapy or Combination | Phage stage | Clinical trials NO. | Status |
---|---|---|---|---|---|---|---|
Evorpacept (ALX148) | Alex Therapeutic | mutated SIRPα-Fc IgG1 | Metastatic Cancer, Solid Tumor, Advanced Cancer, NHL | monotherapy, Pembrolizumab, Trastuzumab, rituximab, Pembrolizumab+ 5-FU + Cisplatin, Trastuzumab+Ramucirumab+Paclitaxel | Phase I | NCT03013218 | 174 participants, Active, not recruiting |
Higher Risk Myelodysplastic Syndrome | Azacitidine | Phase I | NCT04417517 | 173 participants, Recruiting | |||
HNSCC | Pembrolizumab | Phase II | NCT04675294 | 183 participants, Recruiting | |||
HNSCC | Pembrolizumab+Cisplatin/Carboplatin+5FU | Phase II | NCT04675333 | 168 participants, | |||
AML | Venetoclax, Azacitidine | Phase I/II | NCT04755244 | 97 participants, Recruiting | |||
HER2+ gastric cancer | Trastuzumab, Ramucirumab, Paclitaxel | Phase II/III | NCT05002127 | 450 participants, Recruiting | |||
Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma | Lenalidomide+Rituximab | Phase I/II | NCT05025800 | 52 participants, Recruiting | |||
HER2+ gastric cancer | Zanidatamab | Phase Ib/II | NCT05027139 | 93 participants, Recruiting | |||
Microsatellite Stable Metastatic Colorectal Cancer | Cetuximab+Pembrolizumab | Phase II | NCT05167409 | 80 participants, Not yet recruiting | |||
TTI-621 | Trillium Therapeutics | SIRPα-Fc IgG1 | Hematologic Malignancies and Selected Solid Tumors | monotherapy, Rituximab and Nivolumab | Phase I | NCT02663518 | 260 participants, Recruiting |
R/R Solid Tumors and Mycosis Fungoides | monotherapy, PD-1/PD-L1 Inhibitor, pegylated interferon-α2a, T-Vec, radiation | Phase I | NCT02890368 | 56 participants, terrminated | |||
Leiomyosarcoma | Doxorubicin | Phase I/II | NCT04996004 | 80 participants, Recruiting | |||
Multiple Myeloma | Daratumumab Hyaluronidase-fihj | Phase I | NCT05139225 | 40 participants, Recruiting | |||
TTI-622 | SIRPα-Fc IgG4 | Lymphoma, myeloma | monotherapy, Rituximab, PD-1 Inhibitor, Proteasome-inhibitor Regimen | Phase I | NCT03530683 | 150 participants, Recruiting | |
Multiple Myeloma | Daratumumab Hyaluronidase-fihj | Phase I | NCT05139225 | 40 participants, Recruiting | |||
Platinum-Resistant Ovarian Cancer | Pegylated Liposomal Doxorubicin | Phase I/II | NCT05261490 | 50 participants, Recruiting | |||
IMM01 | ImmunoOnco | mutated SIRPα-Fc IgG1 | AML, MDS | Azacitidine | Phase I/II | NCT05140811 | 76 participants, Not yet recruiting |